NVO Novo Nordisk

Novo Nordisk A/S (NOVO-B.KO) 1Q Earnings 
Due: May 1 at 0630 GMT 
Reuters Survey of 23 Analysts 
Average Revenue: DKK21.13B, up 5.8% (DKK19.98B in Q1 2013) 
Average Ebit: DKK7.87B, up 4.1% (DKK7.56B in Q1 2013) 
Average Net Profit: DKK6.35B, up 6.2% (DKK5.98B in Q1 2013) 
 

Note: As guided, the year is expected to start relatively slowly for Novo Nordisk reflecting among other things the impact from losing the express scripts contract. However, since the company has several good-selling products, like Victoza and Levemir, as well as a strong footprint in the U.S., sales growth measured in DKK is still expected to be 5.8%. Watch for possible lowering of 2014 expectations measured in DKK due to weak USD. (clemens.bomsdorf@dowjones.com)

 
Contact us in London: +44-20-7842-9464 
Markettalk.eu@dowjones.com 
 

Subscribe to WSJ: http://online.wsj.com?mod=djnwires